Yan Liu1, Xiao-jian Zhu2, Chen Zeng2, Pin-hui Wu2, Hong-xiang Wang3, Zhi-chao Chen2, Qiu-bai Li2. 1. 1] Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China [2] Department of Hematology, Affiliated Hospital of Taishan Medical College, Taian 271000, China. 2. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 3. Department of Hematology, Wuhan Central Hospital, Wuhan 430022, China.
Abstract
AIM: To investigate whether human multiple myeloma (MM) cells secrete microvesicles (MVs) and whether the MVs secreted from MM cells (MM-MVs) promote angiogenesis. METHODS: RPMI8226 human MM cells and EA.hy926 human umbilical vein cells were used. MVs isolated from RPMI8226 cells were characterized under laser confocal microscopy, electron microscopy and with flow cytometry. The fusion of MM-MVs and EA.hy926 cells was studied under confocal microscopy, and the transfer of CD138 to EA.hy926 cells was demonstrated with flow cytometry. The proliferation, invasion and tube formation of EA.hy926 cells in vitro were evaluated using MTT, transwell migration and tube formation assays, respectively. The vasculization of EA.hy926 cells in vivo was studied using Matrigel plug assay. The expression of IL-6 and VEGF was analyzed with PCR and ELISA. RESULTS: MM-MVs from the RPMI 8226 cells had the characteristic cup-shape with diameter of 100-1000 nm. Most of the MM-MVs expressed phosphatidylserine and the myeloma cell marker CD138, confirming that they were derived from myeloma cells. After added to EA.hy926 cells, the MM-MVs transferred CD138 to the endothelial cells and significantly stimulated the endothelial cells to proliferate, invade, secrete IL-6 and VEGF, two key angiogenic factors of myeloma, and form tubes in vitro and in vivo. CONCLUSION: Our results confirm the presence of MVs in MM cells and support the idea that MM-MVs are newfound mediators for myeloma angiogenesis and may serve as a therapeutic target to treat MM.
AIM: To investigate whether humanmultiple myeloma (MM) cells secrete microvesicles (MVs) and whether the MVs secreted from MM cells (MM-MVs) promote angiogenesis. METHODS: RPMI8226 human MM cells and EA.hy926 human umbilical vein cells were used. MVs isolated from RPMI8226 cells were characterized under laser confocal microscopy, electron microscopy and with flow cytometry. The fusion of MM-MVs and EA.hy926 cells was studied under confocal microscopy, and the transfer of CD138 to EA.hy926 cells was demonstrated with flow cytometry. The proliferation, invasion and tube formation of EA.hy926 cells in vitro were evaluated using MTT, transwell migration and tube formation assays, respectively. The vasculization of EA.hy926 cells in vivo was studied using Matrigel plug assay. The expression of IL-6 and VEGF was analyzed with PCR and ELISA. RESULTS: MM-MVs from the RPMI 8226 cells had the characteristic cup-shape with diameter of 100-1000 nm. Most of the MM-MVs expressed phosphatidylserine and the myeloma cell marker CD138, confirming that they were derived from myeloma cells. After added to EA.hy926 cells, the MM-MVs transferred CD138 to the endothelial cells and significantly stimulated the endothelial cells to proliferate, invade, secrete IL-6 and VEGF, two key angiogenic factors of myeloma, and form tubes in vitro and in vivo. CONCLUSION: Our results confirm the presence of MVs in MM cells and support the idea that MM-MVs are newfound mediators for myeloma angiogenesis and may serve as a therapeutic target to treat MM.
Authors: B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast Journal: Blood Date: 2000-04-15 Impact factor: 22.113
Authors: Gaëlle Gonzalez; Cyrielle Vituret; Attilio Di Pietro; Marc Chanson; Pierre Boulanger; Saw-See Hong Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Deyi Xiao; Samantha Barry; Daniel Kmetz; Michael Egger; Jianmin Pan; Shesh N Rai; Jifu Qu; Kelly M McMasters; Hongying Hao Journal: Cancer Lett Date: 2016-04-07 Impact factor: 8.679
Authors: F Morandi; D Marimpietri; A L Horenstein; M Bolzoni; D Toscani; F Costa; B Castella; A C Faini; M Massaia; V Pistoia; N Giuliani; F Malavasi Journal: Oncoimmunology Date: 2018-05-07 Impact factor: 8.110
Authors: Nuri Lee; Hyewon Lee; Soo Young Moon; Ji Yeon Sohn; Sang Mee Hwang; Ok Jin Yoon; Hye Sun Youn; Hyeon Seok Eom; Sun Young Kong Journal: Ann Lab Med Date: 2015-11 Impact factor: 3.464